Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

• Published in: Alimentary pharmacology & therapeutics Vol. 51; no. 6; pp. 612 - 628
• Main Authors: Gibson, David J., Ward, Mark G., Rentsch, Clarissa, Friedman, Antony B., Taylor, Kirstin M., Sparrow, Miles P., Gibson, Peter R.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2020
• Subjects: Immunotherapy; Inflammatory bowel disease; Inflammatory bowel diseases; Infliximab; Intestine; Monoclonal antibodies; Mucosa; Pharmacodynamics; Pharmacokinetics; Remission; Toxicity; Tumor necrosis factor-α

Background Clinical application of therapeutic drug monitoring (TDM) to optimise anti‐TNF therapies in patients with IBD depends upon target ranges. Aims To review methodology used to determine therapeutic ranges and critically compare and contrast its application to infliximab and adalimumab. Metho...